AB Science Publication of Preclinical Results Demonstrates That masitinib Can Act as a Potentiator of Chemotherapies
PARIS--(BUSINESS WIRE)--Regulatory News: AB Science SA (Paris:AB) (NYSE-Euronext - FR0010557264 - AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), announces publication in The Veterinary Journal of results from a preclinical study showing that masitinib has potential as a chemosensitizer.